SNG
NEUTRALSynairgen to delist from public market
The respiratory company is updating shareholders on its plans to re-register as a private limited company following a recent general meeting.
SNG
0.00%
Market Cap
Volume
0
NaN% of avg
P/E Ratio
N/A
EPS (TTM)
N/A
Beta
N/A
Day Range
p - p
52 Week Range
N/AppN/Ap
p
Upcoming Events
9 April 2027
Asset Match trading facility ends
No data available for this timeframe
SNG
BADSynairgen to delist from AIM, become private company
The healthcare company is proposing to cancel its shares from trading on AIM and re-register as a private limited company after failing to raise the minimum required funds.
SNG
NEUTRALSynairgen Announces Major Shareholder Change
Regulatory filing for a change in major shareholding in this biotechnology company.
SNG
NEUTRALSynairgen Appoints Experienced Healthcare Leader to Board
The healthcare company has appointed an experienced life sciences leader to its Board of Directors, strengthening its expertise as it prepares for a critical clinical trial.
SNG
GOODSynairgen secures £18m to fund Phase 2 trial of SNG001
The respiratory company has raised £18 million to fund a Phase 2 trial of its antiviral drug SNG001 in ventilated patients with severe viral lung infections.
SNG
VERY BADSynairgen Secures £18M Funding for Crucial Respiratory Drug Trial
Biotech secures vital funding for trial
SNG
NEUTRALSynairgen Issues New Shares Following Option Exercise
Biotech firm issues new shares
SNG
NEUTRALSynairgen Reports Progress in SNG001 Development Amid Financial Challenges in H1 2024 Interim Results
The biotechnology firm reported a reduced loss of £3.7 million for H1 2024, down from £5.2 million in H1 2023, while advancing preparations for a Phase 2 trial of its SNG001 treatment for severe viral lung infections.
SNG
NEUTRALSynairgen Appoints New Chairman Ahead of AGM
The respiratory company announces the appointment of a new Chairman, Mark Parry-Billings, who will succeed the retiring Simon Shaw. The company will also hold its Annual General Meeting in October.
SNG
NEUTRALSynairgen Announces Board Change
The respiratory company announces the departure of a long-serving board member, with the clinical leadership remaining unchanged.